Literature DB >> 15308760

The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.

Harry J Witchel1, Christopher E Dempsey, Richard B Sessions, Matthew Perry, James T Milnes, Jules C Hancox, John S Mitcheson.   

Abstract

The molecular determinants of high-affinity human ether-a-go-go-related gene (HERG) potassium channel blockade by methanesulfonanilides include two aromatic residues (Phe656 and Tyr652) on the inner helices (S6) and residues on the pore helices that face into the inner cavity, but determinants for lower-affinity HERG blockers may be different. In this study, alanine-substituted HERG channel mutants of inner cavity residues were expressed in Xenopus laevis oocytes and were used to characterize the HERG channel binding site of the antiarrhythmic propafenone. Propafenone's blockade of HERG was strongly dependent on residue Phe656 but was insensitive or weakly sensitive to mutation of Tyr652, Thr623, Ser624, Val625, Gly648, or Val659 and did not require functional inactivation. Homology models of HERG based on KcsA and MthK crystal structures, representing the closed and open forms of the channel, respectively, suggest propafenone is trapped in the inner cavity and is unable to interact exclusively with Phe656 in the closed state (whereas exclusive interactions between propafenone and Phe656 are found in the open-channel model). These findings are supported by very slow recovery of wild-type HERG channels from block at -120 mV, but extremely rapid recovery of D540K channels that reopen at this potential. The experiments and modeling suggest that the open-state propafenone binding-site may be formed by the Phe656 residues alone. The binding site for propafenone (which may involve pi-stacking interactions with two or more Phe656 side-chains) is either perturbed or becomes less accessible because of closed-channel gating. This provides further evidence for the existence of gating-induced changes in the spatial location of Phe656 side chains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308760     DOI: 10.1124/mol.104.001743

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  27 in total

1.  High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943.

Authors:  Hongwei Cheng; Yihong Zhang; Chunyun Du; Christopher E Dempsey; Jules C Hancox
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.

Authors:  Sheng-na Han; Xiao-yan Sun; Zhao Zhang; Li-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-03-23       Impact factor: 6.150

3.  State dependent dissociation of HERG channel inhibitors.

Authors:  D Stork; E N Timin; S Berjukow; C Huber; A Hohaus; M Auer; S Hering
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

4.  Interactions of H562 in the S5 helix with T618 and S621 in the pore helix are important determinants of hERG1 potassium channel structure and function.

Authors:  James P Lees-Miller; Julia O Subbotina; Jiqing Guo; Vladimir Yarov-Yarovoy; Sergei Y Noskov; Henry J Duff
Journal:  Biophys J       Date:  2009-05-06       Impact factor: 4.033

5.  Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.

Authors:  M J McPate; R S Duncan; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

6.  Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel.

Authors:  Roope Männikkö; G Overend; C Perrey; C L Gavaghan; J-P Valentin; J Morten; M Armstrong; C E Pollard
Journal:  Br J Pharmacol       Date:  2009-08-10       Impact factor: 8.739

7.  Molecular basis for class Ib anti-arrhythmic inhibition of cardiac sodium channels.

Authors:  Stephan A Pless; Jason D Galpin; Adam Frankel; Christopher A Ahern
Journal:  Nat Commun       Date:  2011-06-14       Impact factor: 14.919

8.  Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.

Authors:  Sabrina Obers; Ingo Staudacher; Eckhard Ficker; Adrienne Dennis; Ronald Koschny; Hande Erdal; Ramona Bloehs; Jana Kisselbach; Christoph A Karle; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-13       Impact factor: 3.000

9.  A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.

Authors:  Lei Du-Cuny; Lu Chen; Shuxing Zhang
Journal:  J Chem Inf Model       Date:  2011-10-13       Impact factor: 4.956

10.  Molecular determinants of hERG channel block by terfenadine and cisapride.

Authors:  Kaichiro Kamiya; Ryoko Niwa; Mikio Morishima; Haruo Honjo; Michael C Sanguinetti
Journal:  J Pharmacol Sci       Date:  2008-11-06       Impact factor: 3.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.